Overview
Availability
- Associate Professor Bryan Chan is:
- Available for supervision
Works
Search Professor Bryan Chan’s works on UQ eSpace
2026
Journal Article
“It Will Only Work If Everyone is on Board”: A Needs and Context Assessment to Inform Exercise Oncology Implementation Within a Public Healthcare Organisation
White, Georgia L., Kennedy, Mary A., Chan, Bryan A., Wright, Hattie and Rose, Grace L. (2026). “It Will Only Work If Everyone is on Board”: A Needs and Context Assessment to Inform Exercise Oncology Implementation Within a Public Healthcare Organisation. Asia-Pacific Journal of Clinical Oncology ajco.70158. doi: 10.1111/ajco.70158
2026
Journal Article
SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB Non-Small Cell Lung Cancer
Shu, Catherine A., Kim, Anthony W., Hong, Min Hee, Martinez Marti, Alex, Früh, Martin, Ferris, Andrea, Pass, Harvey, Chan, Bryan A., Waqar, Saiama N., Bernaards, Coen A., Patil, Namrata S., Hsu, Jessie J., Parsons, Cristal, Troutman, Sarah, Matheny, Christina, Li, Pao-Chen, Gitlitz, Barbara and Felip, Enriqueta (2026). SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB Non-Small Cell Lung Cancer. JTO Clinical and Research Reports 101047, 101047. doi: 10.1016/j.jtocrr.2026.101047
2026
Journal Article
Treatment‐related adverse events and health‐related quality of life associated with immune checkpoint inhibitor treatment for mucosal head and neck squamous cell carcinoma: a scoping review
O'Donnell, N. D., Ward, E. C., Wishart, L. R., Perera, R., Barrett, C., Edmiston, K. A., Mitchell, E., Pigott, A., Pitt, R., Russell, K., Chan, B. A. and Ladwa, R. (2026). Treatment‐related adverse events and health‐related quality of life associated with immune checkpoint inhibitor treatment for mucosal head and neck squamous cell carcinoma: a scoping review. Head and Neck hed.70306. doi: 10.1002/hed.70306
2026
Conference Publication
First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01
Chan, Bryan Anthony, Peters, Solange, Leon, Luis, Yamada, Tadaaki, Makani, Neeharika Srivastava, Huang, Wen-Tsung, Spyratos, Dionisios, Roubec, Jaromir, Reinmuth, Niels, Sacher, Adrian G., Spira, Alexander I., Singhal, Nimit, Takeuchi, Shinji, Murciano-Goroff, Yonina R., Zhou, Yanhong, Fink, Aaron Alan, Merced, Alyson, Willard, Melinda D., Visseren Grul, Carla M. and Johnson, Melissa Lynne (2026). First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01. 2026 ASCO Annual Meeting, Chicago, IL United States, 29 May-2 June 2026. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2026.44.16_suppl.8628
2026
Journal Article
Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma
Kok, Peey-Sei, Chan, Bryan, Aberoumoud, Mason, Zhang, Alison, O’Byrne, Ken, Thavaneswaran, Subotheni, Lin, Frank, Kansara, Maya, Corpuz, Theresa, Wheeler, Patrick, Simes, Robert John, Thomas, David and Lee, Chee Khoon (2026). Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma. JTO Clinical and Research Reports, 7 (7) 101014, 101014-7. doi: 10.1016/j.jtocrr.2026.101014
2026
Journal Article
440TiP A phase II/III trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with chemotherapy in first-line for extensive-stage small cell lung cancer (Symbiotic-Lung-04)
Cappuzzo, F., Schaefer, E., Yamanaka, Y., Chan, B.A., Nagrial, A.M., Wu, Y-L., Planchard, D., Gröpper, S., Simoes Da Rocha, P.F., Novello, S., Park, J., Huang, M. and Dowlati, A. (2026). 440TiP A phase II/III trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with chemotherapy in first-line for extensive-stage small cell lung cancer (Symbiotic-Lung-04). ESMO Open, 11 106754, 106754. doi: 10.1016/j.esmoop.2026.106754
2026
Journal Article
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation testing trends, prevalence, and outcomes in metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) patients in Queensland, Australia from 2014–2023
Niranjan, Navin, Guan, Tracey, Niranjan, Nitin, Taherian Fard, Atefeh, Youlden, Danny R., Mason, Robert, Chan, Bryan A. and Sanmugarajah, Jasotha (2026). Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation testing trends, prevalence, and outcomes in metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) patients in Queensland, Australia from 2014–2023. Thoracic Cancer, 17 (7) e70274. doi: 10.1111/1759-7714.70274
2026
Journal Article
Management of bone health in cancer survivorship: a systematic review of clinical guidelines
Li, Victor Ki Chung, Cosgrove, Stirling, Collins, Katelyn, Baden, Paul, Blennerhassett, Richard, Chan, Bryan A., Chan, Li-Heng, Day, Daphne, Goodwin, Belinda, Kwok, Alastair, Packham, Debbie, Kyaw, Kaung Tha, Todaro, Christopher, Webber, Kate, Williams, Janne, Zengin, Ayse and Grech, Lisa (2026). Management of bone health in cancer survivorship: a systematic review of clinical guidelines. Osteoporosis International. doi: 10.1007/s00198-026-07924-8
2026
Conference Publication
Olomorasib+Pembrolizumab in KRAS G12C-Mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01
Johnson, M L, Mateos, L L, Yamada, T, Makani, N, Chan, B, Huang, W-T, Spyratos, D, Roubec, J, Reinmuth, N, Sacher, A, Spira, A, Singhal, N, Takeuchi, S, Murciano-Goroff, Y, Zhou, Y, Fink, A, Fasnacht, N, Willard, M, Visseren-Grul, C, Peters, S and Wesseler, C (2026). Olomorasib+Pembrolizumab in KRAS G12C-Mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01. STUTTGART: Georg Thieme Verlag KG. doi: 10.1055/s-0046-1816480
2026
Journal Article
Facilitators to the implementation of exercise into cancer care: a systematic review
White, Georgia L., Kennedy, Mary A., Cunningham, Brent J., Dunn, Riley, Martin, Jason, Walker, Meegan, Wallington-Gates, Craig T., Wright, Hattie, Chan, Bryan and Rose, Grace L. (2026). Facilitators to the implementation of exercise into cancer care: a systematic review. Journal of Cancer Survivorship. doi: 10.1007/s11764-025-01948-5
2026
Journal Article
Evolving patterns of care, outcomes and ongoing challenges for early‐stage non‐small cell lung cancer in the immunotherapy era: a Queensland population‐based study
Chan, Bryan A., Youlden, Danny R., Pattison, Andrew, Guan, Tracey, Cossio, Danica and Sanmugarajah, Jasotha (2026). Evolving patterns of care, outcomes and ongoing challenges for early‐stage non‐small cell lung cancer in the immunotherapy era: a Queensland population‐based study. Thoracic Cancer, 17 (2) e70185, 1-12. doi: 10.1111/1759-7714.70185
2025
Conference Publication
Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma
Kok, P. S., Chan, B., Zhang, A., O'byrne, K., Aberoumoud, M., Thavaneswaran, S., Lin, F. P., Kansara, M., Corpuz, T., Wheeler, P., Simes, J., Thomas, D. M. and Lee, C. K. (2025). Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2025.10.1018
2025
Journal Article
Setting the benchmark: patterns of care and outcomes for early-stage non-small cell lung cancer in Queensland, Australia, 2011-2017
Chan, Bryan A., Youlden, Danny R., Guan, Tracey, Lehman, Margot, Windsor, Morgan, Bolton, Alison, Dunn, Nathan, Cossio, Danica, Philpot, Shoni and Sanmugarajah, Jasotha (2025). Setting the benchmark: patterns of care and outcomes for early-stage non-small cell lung cancer in Queensland, Australia, 2011-2017. Asia-Pacific Journal of Clinical Oncology, 21 (6), 597-606. doi: 10.1111/ajco.14177
2025
Conference Publication
Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
Johnson, M. L., Mateos, L. L., Yamada, T., Makani, N., Chan, B., Huang, W. T., Spyratos, D., Roubec, J., Reinmuth, N., Sacher, A., Spira, A. I., Singhal, N., Takeuchi, S., Murciano-Goroff, Y. R., Zhou, Y., Fink, A. A., Merced, A., Willard, M. D., Visseren-Grul, C. and Peters, S. (2025). Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01. NEW YORK: ELSEVIER SCIENCE INC.
2025
Conference Publication
Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced<i> KRAS</i> G12C NSCLC
Lee, C. K., Zhou, D. d. -x., Brown, C. S. B., Bray, V., Ding, P., Itchins, M., Hughes, B. G. M., Houghton, B., Chan, B., Black, A., Solomon, B. J., Roberts-Thomson, R., Mersiades, A. J., Parakh, S., Bain, N., Yip, S., Barton, K., Cummins, M. M., Wall, M., Goodwin, A., Stockler, M., Pavlakis, N., John, T. and Arulananda, S. (2025). Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC. NEW YORK: ELSEVIER SCIENCE INC.
2025
Journal Article
Treatment and survival for unresectable pancreatic adenocarcinoma in Queensland, Australia, 2018–2022
Youlden, Danny R., Chan, Bryan A., Clark, Jon, Donoghue, Victoria K. and Allen, Michael J. (2025). Treatment and survival for unresectable pancreatic adenocarcinoma in Queensland, Australia, 2018–2022. Cancer Medicine, 14 (17) e71226, 1-10. doi: 10.1002/cam4.71226
2025
Journal Article
Triage tools to inform the prioritisation of physical health services following a diagnosis of cancer: a scoping review
White, Georgia L., Capozzi, Lauren C., Linton, Corey, Wright, Adrian, Jones, Tamara, Wright, Hattie H., Bolam, Kate A., Johnston, Elizabeth A., Clifford, Briana K., Bean, Keegan, Brown, Stephanie, Kolesaric, Sarah, Kennedy, Mary A., Chan, Bryan A. and Rose, Grace L. (2025). Triage tools to inform the prioritisation of physical health services following a diagnosis of cancer: a scoping review. Supportive Care in Cancer, 33 (9) 760, 1-13. doi: 10.1007/s00520-025-09816-9
2025
Journal Article
Quality indicators for non‐small cell lung cancer in Queensland, Australia, 2012–2021
Youlden, Danny R., Guan, Tracey, Chan, Bryan A., Sanmugarajah, Jasotha, Lehman, Margot, Windsor, Morgan, Bolton, Alison, Nath, Artika, Dunn, Nathan and Cossio, Danica (2025). Quality indicators for non‐small cell lung cancer in Queensland, Australia, 2012–2021. Thoracic Cancer, 16 (5) e70034, e70034. doi: 10.1111/1759-7714.70034
2024
Journal Article
Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort study
Chow, Kar Ven Cavan, Turner, Cassie, Hughes, Brett, Lwin, Zarnie and Chan, Bryan (2024). Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort study. Asia-Pacific Journal of Clinical Oncology, 20 (6), 723-730. doi: 10.1111/ajco.14098
2024
Conference Publication
Reducing preventable emergency visits: results from the Oncology Nurse Practitioner-led Rapid Access Clinic (RACE) service at a tertiary regional cancer centre
Mazza, Cassandra, O'Neill, Martina, Ringshaw, Kacy, Collins, Kelly, O'Riley, Lily, Danielsen-Jensen, Madeline, Bradford, Natalie, Gavin, Nicole, Brunelli, Vanessa N. and Chan, Bryan A. (2024). Reducing preventable emergency visits: results from the Oncology Nurse Practitioner-led Rapid Access Clinic (RACE) service at a tertiary regional cancer centre. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13-15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116
Supervision
Availability
- Associate Professor Bryan Chan is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Media
Enquiries
For media enquiries about Associate Professor Bryan Chan's areas of expertise, story ideas and help finding experts, contact our Media team: